Home Tags ALL

Tag: ALL

U.S. FDA Approves Inotuzumab Ozogamicin for Treatment of Patients with R/R...

The United States Food and Drug Administration (FDA) approved inotuzumab ozogamicin (Besponsa™, Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.) for the treatment of...

Inotuzumab ozogamicin Approved in the EU for Adult Patients with Relapsed...

The European Commission has approved inotuzumab ozogamicin (Besponsa®; Pfizer) as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute...

PF 06263507: Targeting Treatment-resistant Childhood Leukemia

Researchers at The University of Manchester have discovered that 5T4, a transmembrane glycoprotein overexpressed by a variety of cancers and correlated with increased invasiveness,...

Study Shows High Remission Rate in Leukemia Patients Treated with Inotuzumab...

In an open-label, randomized Phase III INO-VATE ALL study, also known as study 1022, of the investigational drug inotuzumab ozogamicin, also known as CMC-544 (Pfizer), a...
Leukemia

Ongoing Phase I Clinical Trial of SGN-CD19A Demonstrates Encouraging Activity and...

Phase I interim data from a clinical trial with SGN-CD19A being developed for the treatment of B-cell malignancies, including acute lymphoblastic leukemia or ALL -- shows...

Clinical Trial with Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin...

Earlier today, Pfizer Inc. confirmed that it had discontinued a Phase III randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the...

X